The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Delivering the power of nanomedicine to patients today
Open accessAbstract
The situation of the COVID-19 pandemic reminds us that we permanently need high-value flexible solutions to urgent clinical needs including simplified diagnostic technologies suitable for use in the field and for delivering targeted therapeutics. From our perspective nanotechnology is revealed as a vital resource for this, as a generic platform of technical solutions to tackle complex medical challenges. It is towards this perspective and focusing on nanomedicine that we take issue with Prof Park's recent editorial published in the Journal of Controlled Release. Prof. Park argued that in the last 15 years nanomedicine failed to deliver the promised innovative clinical solutions to the patients (Park, K. The beginning of the end of the nanomedicine hype. Journal of Controlled Release, 2019; 305, 221-222 [1]. We, the ETPN (European Technology Platform on Nanomedicine) [2], respectfully disagree. In fact, the more than 50 formulations currently in the market, and the recent approval of 3 key nanomedicine products (e. g. Onpattro, Hensify and Vyxeos), have demonstrated that the nanomedicine field is concretely able to design products that overcome critical barriers in conventional medicine in a unique manner, but also to deliver within the cells new drug-free therapeutic effects by using pure physical modes of action, and therefore make a difference in patients lives. Furthermore, the >400 nanomedicine formulations currently in clinical trials are expecting to bring novel clinical solutions (e.g. platforms for nucleic acid delivery), alone or in combination with other key enabling technologies to the market, including biotechnologies, microfluidics, advanced materials, biomaterials, smart systems, photonics, robotics, textiles, Big Data and ICT (information & communication technologies) more generally. However, we agree with Prof. Park that " it is time to examine the sources of difficulty in clinical translation of nanomedicine and move forward ". But for reaching this goal, the investments to support clinical translation of promising nanomedicine formulations should increase, not decrease. As recently encouraged by EMA in its roadmap to 2025, we should create more unity through a common knowledge hub linking academia, industry, healthcare providers and hopefully policy makers to reduce the current fragmentation of the standardization and regulatory body landscape. We should also promote a strategy of cross-technology innovation, support nanomedicine development as a high value and low-cost solution to answer unmet medical needs and help the most promising innovative projects of the field to get better and faster to the clinic. This global vision is the one that the ETPN chose to encourage for the last fifteen years. All actions should be taken with a clear clinical view in mind, " without any fanfare", to focus "on what matters in real life", which is the patient and his/her quality of life. This ETPN overview of achievements in nanomedicine serves to reinforce our drive towards further expanding and growing the maturity of nanomedicine for global healthcare, accelerating the pace of transformation of its great potential into tangible medical breakthroughs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Nanoparticles in the clinic: an update
Anselmo, A. C., & Mitragotri, S. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10143 · Cited by 1,766
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 835
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Bonvalot, S., Rutkowski, P. L., Thariat, J., Carrère, S., Ducassou, A., Sunyach, M.-P., Agoston, P., Hong, A., Mervoyer, A., Rastrelli, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30326-2 · Cited by 536
Krauss, A. C., Gao, X., Li, L., Manning, M. L., Patel, P., Fu, W., Janoria, K. G., Gieser, G., Bateman, D. A., Przepiorka, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2990 · Cited by 332
On behalf of the SentiMAG Trialists Group, Douek, M., Klaase, J., Monypenny, I., Kothari, A., Zechmeister, K., Brown, D., Wyld, L., Drew, P., Garmo, H., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3379-6 · Cited by 230
Nanosensors for diagnosis with optical, electric and mechanical transducers
Munawar, A., Ong, Y., Schirhagl, R., Tahir, M. A., Khan, W. S., & Bajwa, S. Z. (2019) · RSC Advances · doi:10.1039/c8ra10144b · Cited by 214
Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme
Jena, L., McErlean, E., & McCarthy, H. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00679-2 · Cited by 176
Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences.
Bressler, N. M., & Bressler, S. B. (2000) · PubMed · Cited by 160
The beginning of the end of the nanomedicine hype
Park, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.044 · Cited by 158
Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics
Givens, B. E., Naguib, Y. W., Geary, S. M., Devor, E. J., & Salem, A. K. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0267-9 · Cited by 142
Therapeutic implications of nanomedicine for ocular drug delivery
Meng, T., Kulkarni, V. R., Simmers, R., Brar, V. S., & Xu, Q. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.006 · Cited by 140
The solid progress of nanomedicine
Martins, J. P., das Neves, J., de la Fuente, M., Celia, C., Florindo, H. F., Günday-Türeli, N., Popat, A., Santos, J. L., Sousa, F., Schmid, R., et al. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00743-2 · Cited by 136
Self-citationEvaluation of nanomedicines: stick to the basics
McNeil, S. E. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.73 · Cited by 126 · cited 1×
“clearance rate and half time elimination may be significantly improved, increasing the therapeutic outcome and also reducing side effects [7].”
Nanomedicines - Tiny particles and big challenges
Marques, M. R. C., Choo, Q., Ashtikar, M., Rocha, T. C., Bremer‐Hoffmann, S., & Wacker, M. G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.003 · Cited by 114
Valenza, M., Chen, J. Y., Di Paolo, E., Ruozi, B., Belletti, D., Ferrari Bardile, C., Leoni, V., Caccia, C., Brilli, E., Di Donato, S., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505413 · Cited by 112
Self-citationIdentification of regulatory needs for nanomedicines
Bremer‐Hoffmann, S., Halamoda‐Kenzaoui, B., & Borgos, S. E. (2018) · Journal of Interdisciplinary Nanomedicine · doi:10.1002/jin2.34 · Cited by 106
Salvalaio, M., Rigon, L., Belletti, D., D’Avanzo, F., Pederzoli, F., Ruozi, B., Marin, O., Vandelli, M. A., Forni, F., Scarpa, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156452 · Cited by 101
Self-citationVilella, A., Belletti, D., Sauer, A. K., Hagmeyer, S., Sarowar, T., Masoni, M., Stasiak, N., Mulvihill, J. J., Ruozi, B., Forni, F., et al. (2017) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2017.12.006 · Cited by 101
Self-citationde Vlieger, J. S. B., Crommelin, D. J. A., Tyner, K., Drummond, D. C., Jiang, W., McNeil, S. E., Neervannan, S., Crist, R. M., & Shah, V. P. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0329-7 · Cited by 100
Gold Nanoparticles for Modulating Neuronal Behavior
Paviolo, C., & Stoddart, P. R. (2017) · Nanomaterials · doi:10.3390/nano7040092 · Cited by 92
Product quality for nanomaterials: current U.S. experience and perspective
Tyner, K. M., Zou, P., Yang, X., Zhang, H., Cruz, C. N., & Lee, S. L. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1338 · Cited by 77
Swenson, C. E., Haemmerich, D., Maul, D. H., Knox, B., Ehrhart, N. P., & Reed, R. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139752 · Cited by 75
Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles
Rigon, L., Salvalaio, M., Pederzoli, F., Legnini, E., Duskey, J. T., D’Avanzo, F., Filippis, C. D., Ruozi, B., Marin, O., Vandelli, M. A., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20082014 · Cited by 66
Self-citationThe two directions of cancer nanomedicine
(2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0597-5 · Cited by 43
Richardson, J. J., & Caruso, F. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00620 · Cited by 40
Metcalfe, S. M., Bickerton, S., & Fahmy, T. M. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161206141744 · Cited by 27
Self-citationPriming the body to receive the therapeutic agent to redefine treatment benefit/risk profile
Germain, M., Meyre, M.-E., Poul, L., Paolini, M. S., Berjaud, C., Mpambani, F., Bergère, M., Lévy, L., & Pottier, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-23140-9 · Cited by 26
Self-citationTargeting central nervous system pathologies with nanomedicines
Mizrahy, S., Gutkin, A., Decuzzi, P., & Peer, D. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1533556 · Cited by 24
NCI Centers of Cancer Nanotechnology Excellence (CCNEs) – A full story to set the record straight
Grodzinski, P. A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.016 · Cited by 19
Nano-Enabled Medicinal Products: Time for an International Advanced Community?
Gioria, S., Caputo, F., & Méhn, D. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0173 · Cited by 10
Self-citation
Cited by
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Medical 4.0 technologies for healthcare: Features, capabilities, and applications
Haleem, A., Javaid, M., Pratap Singh, R., & Suman, R. (2022) · Internet of Things and Cyber-Physical Systems · doi:10.1016/j.iotcps.2022.04.001 · Cited by 468
Clinical translation of nanomedicines: Challenges, opportunities, and keys
Younis, M. A., Tawfeek, H. M., Abdellatif, A. A. H., Abdel-Aleem, J. A., & Harashima, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114083 · Cited by 462
Effects of nanoparticle size, shape, and zeta potential on drug delivery
Öztürk, K., Kaplan, M., & Çalış, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124799 · Cited by 449
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 433
Metadata
- Authors
- Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K. O., Pottier, A., Schiffelers, R., Ceccaldi, A., & Schmid, R.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 326
- Pages
- 164-171
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W3042581126
- Cited by
- 405
- References
- 37
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.